and conventional viral culture once a week as long as they bocytopenia (n = 4) and leukopenia (n = 1) were seen in associwere being followed-up in our institution at least once a week.
Buffy coat samples were tested for cytomegaloviremia by early antigen detection (shell vial culture) and conventional viral culture once a week or more often if clinically indicated. A positive result on either of the two tests was considered evidence of CMV infection. Urine and throat swabs were not Introduction routinely examined. The rapid method for detection of early CMV antigen in Cytomegalovirus (CMV) disease is an important cause of morinfected monolayer harvested at 36-48 h was an immunobidity after allogeneic bone marrow transplantation. 1 CMV infections frequently affect hematopoiesis after transplantation. 2 The rate of CMV infection after autografting is around 40-50%, but CMV disease is comparatively uncommon. [3] [4] [5] [6] [7] [8] [9] CMV infection (viremia or virus excretion) after allografting
Total number of patients 114
requires treatment ('pre-emptive therapy') because untreated
Median age (range) (years) 31 infections often progress to CMV disease. 10 However, data are enzymatic technique employing alkaline phosphatase with a fast red substrate for staining, and has been described in detail elsewhere. 11 For conventional viral culture of buffy coat-rich blood, specimens were inoculated into tissue culture tubes containing confluent monolayers of diploid human embryonic lung fibroblasts which were observed for cytopathic effects over at least 3 weeks.
In calculating the probability of CMV infection, patients were censored at the time of the last test for cytomegaloviremia, relapse, or death.
Treatment of cytomegaloviremia
Detection of cytomegaloviremia was not an indication for therapy. The criteria for therapy were: viremia accompanied by unexplained fever, persistent drop in the blood counts, intestinal symptoms (epigastric pain, heartburn, nausea, or vomiting), or unexplained liver function abnormalities.
The treatment protocol was as follows: 5 mg/kg ganciclovir resolved without any antiviral therapy in 7-31 days (median 7 days). intravenously twice daily for a week followed by 5 mg/kg once daily 5-7 days a week for 2 weeks or until clearance Three patients had clinical evidence of CMV disease in temporal association with viremia, and were treated with ganof viremia (negative early antigen detection). 12 The dose of ganciclovir was adjusted depending upon the creatinine clearciclovir. The first patient had fever and patchy bilateral lung infiltrates 26 days after transplantation. Bronchoscopy and ance.
12 Intravenous immunoglobulin was not used for the treatment of viremia. Foscarnet was used instead of ganciclobronchoalveolar lavage did not identify any organism. He responded to broad-spectrum therapy for opportunistic pathovir in patients with myelosuppression. 12, 13 gens including ganciclovir, clarithromycin, intravenous amphotericin, and antibacterial antibiotics. The second patient developed severe nausea and vomiting with epigastric
Other supportive care
pain along with the viremia 32 days after transplantation. An endoscopy was not performed, and he was presumed to have Antimicrobial prophylaxis and therapy varied in accordance with prevalent practices. If herpes simplex stomatitis was sus-CMV gastritis. The symptoms resolved on ganciclovir in combination with antacids and antiemetics. The third patient pected, acyclovir was administered at the dose of 5 mg/kg intravenously three times a day or 400 mg orally 3-5 times a developed liver function abnormalities concomitant with cytomegaloviremia 14 days after ASCT. Although she was day only as long as there was mucositis. This dose of acyclovir has no effect on CMV infection. 9, 14 Intravenous immunoglobstarted on ganciclovir when the result of the test became available, viremia was later found to have resolved prior to antiulin was not administered routinely.
All research protocols were approved by the local instiviral therapy being given. Liver function abnormalities, however, did not resolve, and were later attributed to reactivation tutional review board. All patients gave informed consent for the transplant.
of hepatitis B. Viremia was seen only on early antigen detection in the first and third patients (negative conventional viral culture), whereas the virus was isolated on conventional culture as well in the second patient. Thus, none had confirmed Results CMV disease. No symptoms suggestive of CMV infection or disease were Over 95% of samples were tested by early antigen detection as well as conventional culture. For each patient, seen in any of the other patients. Transient thrombocytopenia (n = 4) and leukopenia (n = 1) not attributable to any other (median 11) buffy coat samples were tested from just after the transplant to 2-80 weeks (median 16) post-transplant. Twentycause were seen in association with five episodes of viremia including two of the above three symptomatic episodes. The two episodes of cytomegaloviremia were seen 2-36 weeks (median 11) after ASCT in 14 (21%) seropositive patients. As counts recovered in all five patients; with ganciclovir (n = 2) or with spontaneous clearance of viremia (n = 3). No patient Figure 1 shows, the probability of CMV infection in the first 6 months among seropositive patients was 18.6% (95% CI: died with active cytomegaloviremia. Baseline CMV serostatus (positive or negative, data not 10.6-30.6%). Only one seronegative patient developed asymptomatic cytomegaloviremia which resolved sponshown) and occurrence of CMV infection among CMV-seropositive patients (data not shown) as well as among the whole taneously in 3 weeks. The actuarial probability of CMV infection among seronegative patients was 2.1% (95% CI:
group (Figures 2 and 3 ) made no impact on neutrophil or platelet recovery. 0.3-14.2%). The difference between the two groups was significant (P = 0.0006; Figure 1 ).
Of the 22 episodes of viremia seen among seropositive patients, 19 episodes in 11 patients were not accompanied Discussion by any gastrointestinal symptoms, fall in blood counts, lung infiltrates, or liver function abnormalities. In accordance with
We found that CMV infection was relatively uncommon after autologous transplantation for leukemia in CMV-seropositive the treatment policy, these 19 episodes were not treated, and
The lower rate of CMV infections in CMV-seropositive patients seen by us is difficult to explain. The early antigen test used by us 11 is sensitive enough to identify all allograft recipients at risk of CMV disease, and detects cytomegaloviremia in approximately two-thirds of CMV-seropositive patients (or CMV-seronegative patients with CMV-seropositive donors) after allogeneic BMT.
12 It is therefore unlikely that a significant number of CMV infections are being missed by this technique. It is possible that melphalan-based conditioning regimens, as used in the majority of our patients, are not as immunosuppressive as cyclophosphamide-based regimens, and therefore may result in a lower rate of CMV infection. Other recent studies on CMV infections after autografting 15, 16 have also reported low infection rates which are more in keeping with our observation rather than earlier reports. Our observations may not apply to patients conditioned with more intensive regimens or those transplanted with purged or CD34 + selected pressed for a longer period of time and may be at a higher risk of CMV infections. While the morbidity of CMV disease after autografting is reported to be less than that after allografting, 1, 5 it is not negligible, and fatal complications have been described. 5, 7, 8, 17, 18 Reusser et al 7 observed CMV pneumonia in 11 autografted patients which was fatal in nine. Enright et al 17 reported that 12.4% of allograft and 3.3% of autograft recipients developed CMV pneumonitis. The disease was equally severe in both groups of patients with only two of 12 autografted patients with pneumonia surviving. 17 Valteau et al 18 observed five cases of CMV pneumonitis among 165 children undergoing ASCT after high-dose chemotherapy without TBI for a hematologic malignancy or a solid tumor.
A cooperative group study from the European Group for Blood and Marrow Transplantation (EBMT) 8 reported on 21 cases of CMV pneumonia after autografting. The frequency of CMV pneumonia among 2252 patients was 0.8%, and this varied widely from 0 to 8.6% between different centers. The
Figure 3
Platelet recovery to 50 × 10 9 /l in 15 patients with CMV considerable variation in the rates of CMV infection reported infection and 99 patients without CMV infection. There is no signifiafter autografting could be partly explained by the intensity of cant difference.
the conditioning regimen and disease activity at the time of the graft, and needs to be investigated prospectively using different techniques (PCR, early antigen detection, and convenpatients, and was exceptional in CMV-seronegative patients transfused exclusively with CMV-seronegative blood protional viral culture) prospectively to ascertain the incidence of CMV infection after autografting. Patients with CMV infection ducts. We also found that few autograft recipients with CMV infection actually required pre-emptive therapy because could then be randomized to pre-emptive antiviral therapy or observation to study the need of antiviral therapy in untreated, asymptomatic patients did not progress to CMV disease. Based upon these findings, we have stopped routine preventing progression to CMV disease. The lack of any effect of CMV serostatus or infection on screening for cytomegaloviremia in autografted leukemia patients. The only prophylactic measure we employ in the sethematopoietic recovery is in keeping with the observations of Reusser et al. 7 We have shown that a number of different facting of autografting is the exclusive use of CMV-negative blood products in CMV-seronegative patients.
tors including the source of the cells (marrow or blood), diagnosis, stage, cell dose, and the remission-transplant interval The infection rate observed by us is lower than that reported in two other large series. 5, 7 Wingard et al 5 detected CMV affect recovery after unpurged autografting for acute leukemia. 19 Verdonck et al 20 initially showed slow platelet recovery infection in 65 of 143 (45%) ASCT recipients. Although the incidence of CMV infection was comparable after autologous with CMV infection after autografting, but later found that this effect was seen only in lymphoma. 21 Rowley et al 22 found that and allogeneic BMT, CMV pneumonitis was less frequent in autologous BMT patients (2 vs 12%, P Ͻ 0.001). Reusser et CMV infection during the aplastic period delayed neutrophil but not platelet recovery in patients receiving 4-HC-purged al 7 found that the probability of CMV infection by day 100 after autologous transplantation was 22.5% in CMV-seroneggrafts. It is possible that purging may have rendered the graft more susceptible to an effect of CMV. ative patients and 61.1% in seropositive patients (P Ͻ 0.0001). However, the frequency of virus excretion in the throat or in
We conclude that cytomegaloviremia may not be a clinically significant problem after unmanipulated autografting the urine was considerably more than in the blood. The probability of CMV infection in the blood (cytomegaloviremia) was in patients with leukemia, and may not require antiviral therapy. Therefore, routine monitoring of all autograft recipients 9.1% in CMV-seronegative patients and 8.2% in seropositive patients (P = NS), figures which are comparable to ours.
for CMV infection may not be necessary. 
